Skip to main content
. 2018 Oct 6;8(18):5106–5125. doi: 10.7150/thno.26585

Table 2.

Estimated absorbed doses for optimized anti-HER2-DOTA-PRIT with 177Lu-DOTA-Bn in nude mice carrying s.c. HER2(+) BT-474 tumors, based on serial biodistribution data from 1.0-336 h p.i. of 177Lu-DOTA-Bn (30 pmol).

Tissue 177Lu-DOTA-Bn
(cGy/MBq)
177Lu-therapy
Therapeutic Index
Blood 1.4 28
Tumor 39.9
Heart 0.4 100
Lung 1.3 31
Liver 3.3 12
Spleen 0.3 133
Stomach 0.3 133
Small Intestine 0.4 100
Large Intestine 0.8 50
Kidneys 5.6 7
Muscle 0.9 44
Bone 0.7 57